Clinical Trials Logo

Eye Diseases clinical trials

View clinical trials related to Eye Diseases.

Filter by:

NCT ID: NCT05279157 Completed - Keratoconus Clinical Trials

Autologous Adipose-Derived Adult Stem Cell Implantation for Corneal Diseases (ADASCs-CT-CD)

ADASCs-CT-CD
Start date: April 19, 2022
Phase: Phase 2
Study type: Interventional

Cellular therapy of the corneal stroma with implantation of mesenchymal stem cells derived from autologous adipose tissue with or without a carrier (scaffold) composed by decellularized human donor corneal stroma is used in patients with corneal diseases such as corneal dystrophies, and keratoconus. For this purpose, the study planned to assess the enhancement of visual acuity, pachymetric, and aberrometric parameters with implantation of autologous mesenchymal adipose tissue-derived adult stem cells (ADASCs) alone, 120 µm thickness of decellularized or recellularized laminas with ADASCs. Three groups will be included in the study: (1) Implantation of a single dose of ADASCs alone without scaffold. (2) Implantation of decellularized human corneal lamina without ADASCs. (3) Implantation of the recellularized human corneal lamina with ADASCs.

NCT ID: NCT05276063 Active, not recruiting - Eye Diseases Clinical Trials

A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

LIDS
Start date: July 1, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

The overall objective is to study the safety, pharmacokinetics and efficacy of linsitinib (a small molecule IGF-1R inhibitor) administered orally twice daily (BID) vs. placebo, at 24 weeks in the treatment of subjects with active, moderate to severe thyroid eye disease (TED).

NCT ID: NCT05271422 Completed - Dry Eye Disease Clinical Trials

Application of Pulse Electrical Stimulation Around Eye in Dry Eye Disease Patients Scheduled for LASEK Surgery

Start date: February 28, 2020
Phase: N/A
Study type: Interventional

This study aims to evaluate the efficacy and safety of applying pulse electrical stimulation around eye in dry eye disease patients who are scheduled for LASEK surgery.

NCT ID: NCT05247099 Not yet recruiting - Children Clinical Trials

Pediatric Eye Care Investigated Team

PECT
Start date: February 2022
Phase:
Study type: Observational

Use cohort research to analyze and compare eyes of healthy children and children with systemic diseases. Understand and analyze the incidence, characteristics and influencing factors of children's ocular surface diseases. Establish a multi-center children's eye data sharing platform to provide basic data support for the diagnosis and treatment of children's ocular surface diseases.

NCT ID: NCT05245604 Recruiting - Dry Eye Syndrome Clinical Trials

Evaluating the Efficacy and Safety of TJO-087 in Moderate to Severe Dry Eye Disease Patients

Start date: June 19, 2020
Phase: Phase 3
Study type: Interventional

The purpose of this clinical study is to prove that the test drug (TJO-087) is not clinically inferior to the control drug after 32 weeks of administration to patients with suppressed tear production due to moderate or severe dry eye syndrome.

NCT ID: NCT05241626 Enrolling by invitation - Thyroid Eye Disease Clinical Trials

AS-OCT of the Cornea in Thyroid Diseases

Start date: May 11, 2021
Phase:
Study type: Observational

use the anterior segment optical coherence tomography (AS-OCT) to evaluate the tear meniscus parameters, total corneal thickness (CT), and epithelial thickness in active and inactive thyroid eye diseases (TED) patients and compare them with age-matched controls.

NCT ID: NCT05241470 Completed - Dry Eye Disease Clinical Trials

Study of ST-100 as Treatment for Dry Eye Disease

Start date: May 17, 2021
Phase: Phase 2
Study type: Interventional

The objective of this study is to compare the safety and efficacy of two different concentrations of ST-100 Ophthalmic Solution to placebo (vehicle) for the treatment of the signs and symptoms of dry eye.

NCT ID: NCT05238597 Completed - Dry Eye Disease Clinical Trials

A Study to Evaluate the Safety, Tolerability, and Efficacy of A197 in Subjects With Dry Eye Disease

Start date: January 25, 2022
Phase: Phase 2
Study type: Interventional

The objectives of this trial are to assess the safety, tolerability and efficacy of A197 ophthalmic solution in comparison to a vehicle control in the treatment of subjects with Dry Eye Disease.

NCT ID: NCT05213156 Completed - Dry Eye Disease Clinical Trials

Concentration of Ofloxacin Into the Aqueous Humour of Patients With Dry Eye Disease

Start date: September 24, 2019
Phase: Phase 4
Study type: Interventional

After topical installation of one drop of 0.3% commercially available ofloxacin (Oxatrex®) four times at intervals of 15min in catarract patients with Dry Eye Disease, aqueous humour samples will be collected intraoperatively, one hour after the last installation. Concentration of ofloxacin in aqueous humour will be measured by HPLC-MS/MS.

NCT ID: NCT05211089 Completed - Eye Diseases Clinical Trials

Manual Versus Automated Choroidal Thickness Measurements Using Swept-source Anterior Segment OCT

Start date: October 1, 2021
Phase:
Study type: Observational

The choroid, which is located between the retina and the sclera, is a connective tissue layer that is densely packed with blood vessels and is responsible for supplying oxygen and nutrients to the retina's periphery. One of the primary functions of the choroid is to support the metabolism of the retinal pigment epithelium (RPE). It is implicated in the pathogenesis of a variety of retinal disorders, including age-related macular degeneration, polypoidal choroidal vasculopathy, central serous chorioretinopathy, and high myopia-associated chorio retinal atrophies. Because choroidal alteration has a fundamental role in the development and progression of these diseases, choroidal thickness provides comprehensive information to physicians. For the study of the choroid, researchers have used ultrasound, magnetic resonance imaging MRI, and Doppler laser, but these methods have limited utility due to a lack of resolution. Contrary to this, indocyanine green (ICG) angiography provides valuable clinical information but does not provide cross-sectional images of the choroid for in vivo research studies. Optical coherence tomography (OCT) has gained in popularity in clinical and experimental ophthalmology over the last decade as a way to acquire detailed, three-dimensional images of the retina . Imaging the entire choroid, on the other hand, has proven to be more difficult due to the significant decline in signal strength beyond the RPE prompted by the pigment in the RPE and choroid and light scattering in the vasculature. The development of improved depth imaging (EDI) by Spaide et al. opened the door to quantitative choroid assessment. Choroid imaging is currently possible using one of two optical coherence tomography (OCT) techniques: (1) spectral-domain (SD) OCT utilizing standard light sources using EDI, and (2) swept-source (SS) OCT using a long wavelength light .A 1 m-band light source is used in SS-OCT, which penetrates deeper into the retino choroidal tissues and so optimizes the resolution. To better visualize retinal and choroidal changes, SS-OCT can concurrently display a focused image of both the retina and the choroid. This renders it an accurate technology for assessing choroidal thickness. Such findings of choroidal thickness changes revealed that the choroid and choroidal thickness may be important attributes in the evaluation of ocular pathology. To properly understand the scientific value of these potential choroidal thickness variations, it would appear that comprehensive and systematic normative values for choroidal thickness are fundamental.